A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
for Non-small Cell Lung Cancer
12 locations incl. Glendale
Sponsor: Shanghai Henlius Biotech
Sex: All·Age: 18 - 85
Code: NCT07160335·Phase 1·Recruiting·Listed Sep 2025